PURCHASE AND SALE AGREEMENT by and among CAMBREX CORPORATION, THE ACQUIRED COMPANIES, THE PERSONS SIGNATORY HERETO AS SELLERS, SK ANGEL HOLDINGS, L.P. AND THE SELLERS’ REPRESENTATIVE Dated as of July 20, 2018Purchase and Sale Agreement • August 2nd, 2018 • Cambrex Corp • Pharmaceutical preparations • Delaware
This Purchase and Sale Agreement, dated as of July 20, 2018 (this “Agreement”), by and among (i) Cambrex Corporation, a Delaware corporation (the “Buyer”), (ii) Halo Pharmaceutical, Inc., a Delaware corporation (“Halo US”), 8121117 Canada Inc., a corporation organized under the laws of Canada (also known as Halo Pharmaceutical Canada Holding, Inc. (or “Halo 812”)) and Halo Pharmaceutical Canada Inc., a corporation organized under the laws of Canada (“Halo Canada” and together with Halo US, Halo 812 and their respective Subsidiaries, collectively the “Acquired Companies” or “Halo”), (iii) each of the persons designated on the signature pages hereto as Sellers (each a “Seller” and, collectively, the “Sellers”), (iv) SK Capital Partners, L.P., a Delaware limited partnership (as the Sellers’ Representative (as defined herein)), and (v) SK Angel Holdings, L.P., a Cayman Islands exempted limited partnership, in its capacity as the Seller guarantor (the “Seller Guarantor”).
